Research Article | Open Access
Hongwei Chen, Jianyu Feng, Yuchen Zhang, Aling Shen, Youqin Chen, Jiumao Lin, Wei Lin, Thomas J. Sferra, Jun Peng, "Pien Tze Huang Inhibits Hypoxia-Induced Angiogenesis via HIF-1α/VEGF-A Pathway in Colorectal Cancer", Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 454279, 8 pages, 2015. https://doi.org/10.1155/2015/454279
Pien Tze Huang Inhibits Hypoxia-Induced Angiogenesis via HIF-1α/VEGF-A Pathway in Colorectal Cancer
Hypoxia-induced angiogenesis plays an important role in the development and metastasis of solid tumors and is highly regulated by HIF-1α/VEGF-A pathway. Therefore, inhibiting tumor angiogenesis via suppression of HIF-1α/VEGF-A signaling represents a promising strategy for anticancer treatment. As a traditional Chinese medicine formula, Pien Tze Huang (PZH) has long been used as a folk remedy for cancer in China and Southeast Asia. Previously, we reported that PZH inhibits colorectal cancer (CRC) growth both in vivo and in vitro. To elucidate the antitumor mechanisms of PZH, in the present study we used human umbilical vein endothelial cells (HUVEC) and colorectal carcinoma HCT-8 cells to evaluate the effects of PZH on hypoxia-induced angiogenesis and investigated the underlying molecular mechanisms. We found that PZH could inhibit hypoxia-induced migration and tube formation of HUVEC cells in a dose-dependent manner, although the low concentrations of PZH had no effect on HUVEC viability. Moreover, PZH inhibited hypoxia-induced activation of HIF-1α signaling and the expression of VEGF-A and/or VEGFR2 in both HCT-8 and HUVEC cells. Collectively, our findings suggest that PZH can inhibit hypoxia-induced tumor angiogenesis via suppression of HIF-1α/VEGF-A pathway.
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer mortality in the developed world . Approximately one million new cases are diagnosed every year and 500,000 deaths are reported annually . CRC is a disease characterized by activation of multiple signaling pathways which stimulate proliferation and angiogenesis as well as invasion and metastasis [3–5]. During the last decade, the survival rate of CRC has increased due to early diagnosis, staging, and improvements in surgery and therapy [6, 7]. However, tumor progression to a highly metastatic stage (mCRC) decreases the overall 5-year survival rate to below 10%, in part due to tumor angiogenesis, which is required for tumor growth and metastasis [8–11].
Angiogenesis is a central mechanism in human colorectal cancer development and growth [12, 13]. In particular, vascular endothelial growth factor (VEGF) is closely associated with the induction of neovascularization in human colon cancer . VEGF is one of the most important endogenous ligands of receptors present on the endothelial cell plasma membrane and its binding leads to intracellular signaling and, ultimately, gene transcription that promotes endothelial proliferation, migration, and tube formation of endothelial cells resulting in tumor growth and metastasis [15, 16]. In addition, VEGF is mediated by multiple interacting genetic and environmental signals . A hypoxic microenvironment that is critical for the tumorigenic process in general can stimulate VEGF via hypoxia inducible factor-1 (HIF-1), its primary regulator during hypoxic conditions.
HIF-1 is a dimeric transcription factor composed of the HIF-1α and HIF-1 subunits. HIF-1α is a key player in the maintenance of cellular homeostasis under hypoxic conditions through its regulation of the expression of many genes involved in a crucial aspect of cancer biology [18–20]. Under normoxic conditions, prolyl hydroxylase mediates the hydroxylation of the proline residues of HIF-1α at two positions that allow HIF-1α to interact with the von Hippel-Lindau E3 ligase complex which allows for degradation by the ubiquitin-proteasome system . Under hypoxic conditions, HIF-1α is not degraded and is able to bind with the ubiquitously expressed HIF-1 subunit. The heterodimeric HIF-1 rapidly translocates to the nucleus, where it binds to the hypoxia-responsive element and regulates several genes responsible for cellular development under hypoxic conditions. One of the HIF-1-responsive genes is VEGF, which promotes angiogenesis in tumors .
Owing to the important role of angiogenesis in the progression and metastasis of solid tumors, inhibition of tumor angiogenesis has become a promising strategy for anticancer chemotherapy. Various kinds of antiangiogenic agents are currently being developed. However, redundancy and cross talk in these pathways form a complicated and robust network which is difficult to target. Currently, angiogenesis inhibitors that target only a single pathway may be insufficient and may contribute to drug resistance . These problems highlight the need for the development of novel anticancer agents. Natural products, such as TCM, have been used as therapies for a very long time [24–26]. Pien Tze Huang (PZH) is a well-known TCM formula that was first prescribed 450 years ago in the Ming Dynasty. PZH has been used in China and Southeast Asia for centuries as a folk remedy for various types of cancer [27, 28]. We have previously reported that PZH can inhibit colon cancer cell growth in vitro via promotion of apoptosis . In addition, using a CRC mouse xenograft model, we found that PZH can suppress tumor growth in vivo without apparent adverse effects and was shown to inhibit vascular endothelial cell proliferation in vitro and capillary tube formation in vivo [30, 31]. The effects of PZH on hypoxia-induced angiogenesis during hypoxic conditions have not been explored.
Here, we show that PZH strongly downregulates the expression of HIF-1α and inhibits angiogenesis in hypoxic conditions. PZH potently inhibited hypoxia-induced transcription and translation of VEGF-A. Moreover, we found that PZH ameliorates hypoxia-stimulated angiogenesis. These results demonstrate that PZH may inhibit hypoxia-induced angiogenesis by downregulating HIF-1α/VEGF-A activity.
2. Materials and Methods
2.1. Materials and Reagents
All chemicals, unless otherwise stated, were obtained from Sigma-Aldrich (St. Louis, MO, USA). Roswell Park Memorial Institute Medium 1640 (RPMI RPMI-1640), penicillin-streptomycin, fetal bovine serum (FBS), Trypsin-EDTA, and TRIzol reagent were purchased from Invitrogen (Carlsbad, CA, USA). SuperScript II reverse transcriptase was obtained from Promega (Madison, WI, USA). In vitro angiogenesis assay kit was purchased from Millipore (Billerica, MA, USA). Enzyme linked immune sorbent assay (ELISA) kits of human VEGF-A were obtained from Shanghai Xitang Biological Technology Ltd. (Shanghai, China). HIF-1α, -actin antibodies, and horseradish peroxidase- (HRP-) conjugated secondary antibodies were purchased from Cell Signaling (Beverly, MA, USA).
2.2. Preparation of PZH
PZH was obtained from and authenticated by the sole manufacturer Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., China (Chinese FDA Approval number Z35020242). Stock solution of PZH was prepared immediately prior to use by dissolving the PZH powder in phosphate buffered saline (PBS) to a concentration of 20 mg/mL.
2.3. Cell Culture
Human umbilical vein endothelial cells (HUVECs) and human colon carcinoma cells (HCT-8) were obtained from Nanjing KeyGen Biotech. Co. Ltd. (Nanjing, Jiangsu, China). HCT-8 and HUVECs cells were grown in RPMI-1640 containing 10% (v/v) FBS and 100 U/mL penicillin and 100 μg/mL streptomycin. Cells were cultured at 37°C, in a 5% CO2 humidified environment (normoxic). To expose the cells to hypoxia, they were placed in a modular incubator chamber (Thermo Forma, Waltham, MA, USA), which was infused with a mixture of 1% O2, 5% CO2, and 94% N2.
2.4. Cell Viability Evaluation
Viability of HUVECs was carried out using a 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Briefly, HUVECs were harvested from exponential phase cultures growing in RPMI-1640 supplemented with 10% FBS, counted, plated in 96-well flat-bottomed microtiter plates (100 μL cell suspensions, 6 × 104 cells/mL for HUVECs cells), and treated with medium containing various concentrations of PZH. After 24 hours, the media were removed and 100 μL of MTT solution (0.5 mg/mL in PBS) was added, and the reaction mixture was incubated at 37°C in a 5% CO2 atmosphere for 4 hours. The MTT solution was removed and 100 μL of DMSO added. Optical density was measured using a spectrophotometer (Bio-Tek Model ELX800, USA) at 570 nm.
2.5. Wound-Healing Cell Migration Assay
HUVECs were plated at 4 × 105 cells/well on a 6-well plate in normal culture media and allowed to reach 80–90% confluency. An injury line with a width of 0.6~1.0 mm was made with a sterile pipette tip and cells were rinsed with PBS. The cells were incubated with serum-free medium supplemented with PZH (0.0625, 0.125, and 0.25 mg/mL) or medium alone as a control in hypoxia (1% O2) or normoxia (21% O2). Wound closure was evaluated 12 hours later with a Leica DMIL inverted microscope (Leica, German).
2.6. Migration Assay
Cell migration assays were performed with transwell cell culture chambers with 8 μm pore filters (Corning, NY, USA). After treatment with various concentrations of PZH under normoxia for 24 hours, HUVECs cells were trypsinized and resuspended in serum-free RPMI 1640. HUVECs (5 × 104 cells in 200 μL of serum-free RPMI 1640) were added to the upper compartment in duplicate filters and RPMI-1640 media containing 10% (v/v) FBS were used as a chemoattractant in the lower chambers. Cells were allowed to migrate for 12 hours in normoxic/hypoxic conditions. The nonmigrating cells were removed from the upper surface of each transwell by cotton swab. Transwell membranes were then stained with crystal violet. For quantification, the average number of migrating cells per field was assessed by counting 5 random fields under a phase-contrast microscope (Leica, German) at 200x magnification.
2.7. Tube Formation Assay
The HUVECs tube formation assay was performed with an ECMatrix assay kit, following the manufacture’s protocol. Briefly, HUVECs cells were seeded in 6-well culture plates at a density of 2 × 105 cells/mL. After overnight incubation, HUVECs were treated with indicated concentrations of PZH for 24 hours in normoxic conditions, harvested and diluted to 2 × 105 cells/well in 200 μL media, seeded into 1 : 1 ECMatix gel (v/v) coated 48-well plates, and incubated at 37°C under normoxic/hypoxic conditions for 6 hours. Tubes were imaged using a phase-contrast inverted microscope (Leica, German) at 100x magnification. The degree of tube formation was quantified by counting the number of tube structures in four randomly chosen fields without overlap.
The secretion level of VEGF was detected by ELISA kit according to the manufacturer’s protocol. The results were expressed as fold change in the concentration of VEGF relative to that of cells in normoxia.
2.9. RT-PCR Assay
Total RNA was extracted from cultured cells using the Trizol reagent (TakaRa). cDNA was synthesized from 2 μg of total RNA with a Reverse Transcription Kit (TakaRa). The primers used in the RT-PCR reactions were the following: (forward primer) 5′-CTC AAA GTC GGA CAG CCT CA-3′ and (reverse primer) 5′-CCC TGC AGT AGG TTT CTG CT-3′ for HIF-1α, (forward primer) 5′-TTT CTG CTG TCT TGG GTG CAT TGG-3′ and (reverse primer) 5′-TCT GCA TGG TGA TGT TGG ACT CCT-3′ for VEGF, and 5′-CTC CAG GGC TTC TTG GTT TTC C-3′ and (reverse primer) 5′-TTT CAC CAT CTG GTT GGC TGG C-3′ for α-tubulin. The PCR products were separated and visualized on an agarose gel stained with ethidium bromide under UV transillumination.
2.10. Western Blot
Cultured cells were lysed in a buffer containing 40 mM Tris-Cl, 10 mM EDTA, 120 mM NaCl, 0.1% NP-40, and a protease inhibitor cocktail (CALBIOCHEM). Protein concentration was determined using a bicinchoninic acid (BCA) assay. Denatured proteins were separated by SDS/polyacrylamide gel electrophoresis (PAGE) and transferred to a PVDF membrane (MILLIPORE). The membrane was incubated with 5% skim milk in TBS containing 0.1% Tween-20 for 1 hour at room temperature and probed with the appropriate antibodies. The blots were developed using an ECL Prime Detection Kit (Amersham Pharmacia Biotech).
3.1. Intrinsic Cytotoxicity of PZH in HUVECs
The lowest dose (0.0625 mg/mL) of PZH was not cytotoxic to HUVECs, and higher doses (0.125 and 0.25 mg/mL) only decreased cell viability by 11.36% and 13.69%, respectively (Figure 1). To investigate angiogenesis inhibition effects of PZH, treatment concentrations of 0.0625–0.25 mg/mL were chosen.
3.2. PZH Inhibited Hypoxia-Induced Migration of HUVECs
Since endothelial cell migration is a pivotal step for angiogenesis, we performed wound-healing and transwell migration assays in HUVECs pretreated with indicated concentrations of PZH (Figure 2) . Dose dependent attenuation of hypoxia-induced increase in migration rates into wounds was observed (Figures 2(a) and 2(c)). Hypoxia alone increased transwell migration by 1.64-fold as compared to normoxia while intervention with PZH lowered hypoxia-induced increased transwell migration rates to below baseline in a dose dependent manner (Figures 2(b) and 2(d)).
3.3. PZH Inhibited Hypoxia-Induced Tube Formation of HUVECs
PZH blunted increased capillary-like networks due to hypoxic conditions in a dose dependent manner as well (Figure 3).
3.4. PZH Inhibited Hypoxia-Induced Expression of HIF-1α and VEGF-A in HCT-8 Cells and HUVECs
HIF-1α is known to be stabilized during hypoxia driving VEGF expression promoting angiogenesis . We therefore examined whether PZH could influence the expression patterns of HIF-1α and VEGF-A in HCT-8 and HUVECs cells exposed to hypoxia. PZH suppressed HIF-1α protein levels as well as mRNA expression in both HUVECs and HCT-8 cells (Figures 4(a), 4(b), 5(a), and 5(b)). Moreover, PZH inhibited hypoxia-induced secretion of VEGF-A in both cell lines as well (Figures 4(c) and 5(c)). These results suggest that downregulated HIF-1α/VEGF-A pathway by PZH could inhibit the hypoxia-stimulated migration and tubular formation of endothelial cells.
HIF-1α, a transcription factor, has been demonstrated to be associated with most hypoxic solid tumors and is consistently upregulated in various types of cancers and promotes tumorigenesis through angiogenesis [19, 34, 35]. Aberrant expression of VEGF is known to be a key regulator in hypoxia-induced angiogenesis. Although PZH is known to inhibit VEGF expression via multiple cellular pathways, the effect of PZH on hypoxia-induced VEGF expression and the regulation of HIF-1α activity by PZH are not well understood . In this study, we have demonstrated that VEGF, a potent hypoxia-induced angiogenic factor, and HIF-1α, the transcription factor essential for VEGF transcriptional activation, can be regulated by PZH in HCT-8 and HUVECs. We further revealed that PZH directly suppresses hypoxia-stimulated endothelial migration and tube formation, which is also accompanied by decreased HIF-1α and VEGF expression levels in PZH-treated HUVECs. A recent report showed that loss of hypoxia-responsive HIF-1α in endothelial cells results in impaired angiogenesis. This impairment is a direct result of the disruption of an autocrine loop acting through HIF-1α regulation of hypoxia-induced VEGF expression . Based on our observations in this project, PZH may play a direct role in the degradation of HIF-1α and subsequent VEGF signaling in colorectal cancer cells and endothelial cells, leading to the inhibition of hypoxia-induced tumor angiogenesis, which is consistent with our previous study that PZH displays antitumor angiogenesis activity in the colorectal cancer mouse xenograft model .
Interestingly, many drugs may enhance vascularization in normal injured tissue while doing the reverse in tumor. Although there are no reports directly demonstrating the effects of Pien Tze Huang (PZH) on vascularization in the normal injured tissue, PZH is believed to be able to promote would healing because it has long been used to clinically treat traumatic injuries. In addition, recently it has been reported that Panax notoginseng saponins (PNS), one of major components in PZH, exerted a significant therapeutic effect on a complex disease condition featuring concomitant presentation of lung carcinoma and myocardial ischemia in mouse, where PNS was able to inhibit tumor angiogenesis and meanwhile promote myocardial ischemia-induced angiogenesis . Therefore, we speculate that PZH probably also bidirectionally regulates angiogenesis: enhancing vascularization in normal injured tissue while doing the reverse in tumors. Although Yang et al. further proposed that PNS bidirectionally regulated angiogenesis through modulating the expression of proangiogenic miR-18a in a tissue specific manner, they did not address why PNS displayed opposite regulation of angiogenesis and related miRNA expression in different tissues. The possible mechanisms mediating the bidirectional angiogenic activity of PNS and other drugs could be the difference of microenvironment between tumors and normal tissues.
It has been shown that tumor blood vessels differ morphologically from their normal counterparts, which display inappropriate growth and abnormal proliferation and apoptosis in endothelial cells, insufficient pericyte recruitment, enhanced leakiness, decreased blood flow, and abnormalities in the basement membrane [37, 38]. Moreover, gene expression analysis of endothelial cells derived from human blood vessels of normal and malignant colorectal tissues revealed that forty-six genes were specifically elevated in tumor-associated endothelium . Furthermore, hypoxia is a common characteristic feature of all rapidly growing solid tumors, which may trigger the activation of tumor-related signaling pathways such as HIF-1α . However, the precise mechanisms of how drugs exert bidirectional angiogenic function remain largely unclear. These intriguing and challenging questions must be addressed by future studies before these drugs can be developed as better antiangiogenic agents for cancer treatment.
Conflict of Interests
The authors declare no financial or commercial conflict of interests.
This work was sponsored by the National Natural Science Foundation of China (81373819 and 81202790) and the China Postdoctoral Science Foundation (2013T60636).
- A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” A Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010.
- E. Chu, “An update on the current and emerging targeted agents in metastatic colorectal cancer,” Clinical Colorectal Cancer, vol. 11, no. 1, pp. 1–13, 2012.
- Y. Y. Zaytseva, V. A. Elliott, P. Rychahou et al., “Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer,” Carcinogenesis, vol. 35, no. 6, pp. 1341–1351, 2014.
- S. Gaur, L. Chen, V. Ann et al., “Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status,” Molecular Cancer, vol. 13, no. 1, article 21, 2014.
- K. Rupertus, J. Sinistra, C. Scheuer et al., “Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer,” Clinical & Experimental Metastasis, vol. 31, no. 4, pp. 447–459, 2014.
- N. Kapse and V. Goh, “Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography,” Clinical Colorectal Cancer, vol. 8, no. 2, pp. 77–87, 2009.
- O. Majek, A. Gondos, L. Jansen et al., “Survival from colorectal cancer in Germany in the early 21st century,” British Journal of Cancer, vol. 106, no. 11, pp. 1875–1880, 2012.
- J. M. Davies and R. M. Goldberg, “Treatment of metastatic colorectal cancer,” Seminars in Oncology, vol. 38, no. 4, pp. 552–560, 2011.
- T. Winder and H.-J. Lenz, “Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer,” Gastroenterology, vol. 138, no. 6, pp. 2163–2176, 2010.
- J. Folkman, “Tumor angiogenesis: therapeutic implications,” The New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971.
- J. Folkman and M. Klagsbrun, “Angiogenic factors,” Science, vol. 235, no. 4787, pp. 442–447, 1987.
- C. A. Staton, A. S. A. Chetwood, L. C. Cameron, S. S. Cross, N. J. Brown, and M. W. R. Reed, “The angiogenic switch occurs at the adenoma stage of the adenoma-carcinoma sequence in colorectal cancer,” Gut, vol. 56, no. 10, pp. 1426–1432, 2007.
- R. S. Warren, H. Yuan, M. R. Matli, N. A. Gillett, and N. Ferrara, “Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis,” The Journal of Clinical Investigation, vol. 95, no. 4, pp. 1789–1797, 1995.
- Y. Takahashi, Y. Kitadai, C. D. Bucana, K. R. Cleary, and L. M. Ellis, “Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer,” Cancer Research, vol. 55, no. 18, pp. 3964–3968, 1995.
- A. M. Byrne, D. J. Bouchier-Hayes, and J. H. Harmey, “Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF),” Journal of Cellular and Molecular Medicine, vol. 9, no. 4, pp. 777–794, 2005.
- X.-Y. Wang, S. Ju, C. Li et al., “Non-invasive imaging of endothelial progenitor cells in tumor neovascularization using a novel dual-modality paramagnetic/near-infrared fluorescence probe,” PLoS ONE, vol. 7, no. 11, Article ID e50575, 2012.
- H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004.
- M. C. Brahimi-Horn, J. Chiche, and J. Pouysségur, “Hypoxia and cancer,” Journal of Molecular Medicine, vol. 85, no. 12, pp. 1301–1307, 2007.
- G. L. Semenza, “HIF-1 and tumor progression: pathophysiology and therapeutics,” Trends in Molecular Medicine, vol. 8, no. 4, pp. S62–S67, 2002.
- G. L. Semenza, “Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy,” Trends in Pharmacological Sciences, vol. 33, no. 4, pp. 207–214, 2012.
- S. Kizaka-Kondoh, S. Tanaka, H. Harada, and M. Hiraoka, “The HIF-1-active microenvironment: an environmental target for cancer therapy,” Advanced Drug Delivery Reviews, vol. 61, no. 7-8, pp. 623–632, 2009.
- S. A. Stacker, C. Caesar, M. E. Baldwin et al., “VEGF-D promotes the metastatic spread of tumor cells via the lymphatics,” Nature Medicine, vol. 7, no. 2, pp. 186–191, 2001.
- H. P. Eikesdal and R. Kalluri, “Drug resistance associated with antiangiogenesis therapy,” Seminars in Cancer Biology, vol. 19, no. 5, pp. 310–317, 2009.
- D. J. Newman, G. M. Cragg, and K. M. Snader, “The influence of natural products upon drug discovery,” Natural Product Reports, vol. 17, no. 3, pp. 215–234, 2000.
- C. Spatafora and C. Tringali, “Natural-derived polyphenols as potential anticancer agents,” Anti-Cancer Agents in Medicinal Chemistry, vol. 12, no. 8, pp. 902–918, 2012.
- H.-F. Ji, X.-J. Li, and H.-Y. Zhang, “Natural products and drug discovery: can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?” EMBO Reports, vol. 10, no. 3, pp. 194–200, 2009.
- Y. Xu and E. Yu, “Clinical analysis of the effect of Pien Tze Huang in treatment of 42 patients with moderate or advanced liver cancer,” Shanghai Journal of Tradition Chinese Medicine, vol. 12, pp. 4–5, 1994.
- Z. Gu, “Therapeutical observation of advanced colon cancer,” Chinese Traditional Patent Medicine, vol. 15, p. 23, 1993.
- J. M. Lin, L. H. Wei, Y. Q. Chen et al., “Pien Tze Huang induced apoptosis in human colon cancer HT-29 cells is associated with regulation of the Bcl-2 family and activation of caspase 3,” Chinese Journal of Integrative Medicine, vol. 17, pp. 685–690, 2011.
- A.-L. Shen, F. Hong, L.-Y. Liu et al., “Effects of Pien Tze Huang on angiogenesis in vivo and in vitro,” Chinese Journal of Integrative Medicine, vol. 18, no. 6, pp. 431–436, 2012.
- A. Shen, J. Lin, Y. Chen et al., “Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways,” Oncology Reports, vol. 30, no. 4, pp. 1701–1706, 2013.
- Y. Song, F. Dai, D. Zhai et al., “Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways,” Angiogenesis, vol. 15, no. 3, pp. 421–432, 2012.
- N. Tang, L. Wang, J. Esko et al., “Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis,” Cancer Cell, vol. 6, no. 5, pp. 485–495, 2004.
- D. E. Richard, E. Berra, and J. Pouysségur, “Angiogenesis: how a tumor adapts to hypoxia,” Biochemical and Biophysical Research Communications, vol. 266, no. 3, pp. 718–722, 1999.
- G. L. Semenza, “HIF-1: using two hands to flip the angiogenic switch,” Cancer and Metastasis Reviews, vol. 19, no. 1-2, pp. 59–65, 2000.
- Q. Yang, X. Wang, J. Cui et al., “Bidirectional regulation of angiogenesis and miR-18a expression by PNS in the mouse model of tumor complicated by myocardial ischemia,” BMC Complementary and Alternative Medicine, vol. 14, article 183, 2014.
- R. K. Jain, “Molecular regulation of vessel maturation,” Nature Medicine, vol. 9, no. 6, pp. 685–693, 2003.
- P. Baluk, S. Morikawa, A. Haskell, M. Mancuso, and D. M. McDonald, “Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors,” The American Journal of Pathology, vol. 163, no. 5, pp. 1801–1815, 2003.
- B. St. Croix, C. Rago, V. Velculescu et al., “Genes expressed in human tumor endothelium,” Science, vol. 289, no. 5482, pp. 1197–1202, 2000.
- H. Kimura, A. Weisz, T. Ogura et al., “Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide,” The Journal of Biological Chemistry, vol. 276, no. 3, pp. 2292–2298, 2001.
Copyright © 2015 Hongwei Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.